



Press release |

RADIOMED ANNOUNCES NEW PATENT ISSUED FOR VISICOIL MARKERS

Bartlett, TN., June 20, 2011 / PRNewswire/ RadioMed Corporation (subsidiary of [IBA](#) Ion Beam Applications, S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) announced today that it was issued a patent from the U.S. Patent Office. The patent, U.S. Patent Number 10/284,037 entitled "Elongated Markers for Soft Tissue Identification" provides a flexible, stable gold marker for targeting tumors and soft tissue. [VISICOIL](#)™ is highly visible under various imaging techniques utilized during radiation treatment for oncology patients.

The [clinical success](#) of focused, dose-delivery procedures such as Intensity Modulated Radiation Therapy (IMRT), conformal radiation therapy (CRT), and Proton Therapy (PT) is based on the accuracy of target identification and precise patient positioning. VISICOIL markers allow for accurate tumor localization utilizing a variety of visualization techniques and help focal radiotherapy procedures through increased stability and visibility.

"We are extremely pleased with the U.S. Patent Office's issuance of this patent, which we believe will strengthen our intellectual property protection. This is a significant milestone for our company and for the innovative VISICOIL product line" says Gordon Roberts, RadioMed Corporation, General Manager. "The VISICOIL patent adds to IBA's patent portfolio of cancer treatment and prevention technology and furthers IBA's mission to Protect, Enhance and Save Lives."

RadioMed Corporation was founded in 1997 as a private corporation and became part of IBA in 2003. The VISICOIL product line includes four different diameters and lengths to aid in the treatment planning for a range of radiation therapy techniques that target the prostate, lung, liver, pancreas, breast and various other organs. IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

###

Contact:

Gordon Roberts
General Manager
RadioMed Corporation Bartlett, TN.
Mobile: +1 978 807 1017
gordon.roberts@iba-group.com